New combo approach may extend life for certain colorectal cancer patients

NCT ID NCT05862051

First seen May 12, 2026 ยท Last updated May 12, 2026

Summary

This study looks at whether adding a targeted treatment (local ablative therapy) to standard first-line chemotherapy can help people with colorectal cancer that has spread to a few spots (oligometastatic) live longer without the cancer getting worse. About 6 participants whose cancer responded to initial chemo will either continue chemo alone or also receive local ablative therapy. The goal is to see if the combination delays cancer progression and improves overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barwon Health

    Geelong, Victoria, 3220, Australia

  • Bendigo Hospital

    Bendigo, Victoria, 3550, Australia

  • Border Medical Oncology

    Albury, New South Wales, 2640, Australia

  • Eastern Health

    Box Hill, Victoria, 3128, Australia

  • Northeast Health Wangaratta

    Wangaratta, Victoria, 3677, Australia

  • Peter MaCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, 3065, Australia

  • The Northern Hospital

    Epping, Victoria, 3076, Australia

  • Western Health

    Saint Albans, Victoria, 3021, Australia

Conditions

Explore the condition pages connected to this study.